Legal Opinion
In re Eliquis (Apixaban) Prods. Liab. Litig.
United States Judicial Panel on Multidistrict Litigation
Decided February 7, 2017No. MDL No. 2754PublishedCited by 3 opinions
1Opinion of the Court
SARAH S. VANCE, Chair
Before the Panel : Defendants Bristol-Myers Squibb Company (BMS) and Pfizer Inc. move under 28 U.S.C. § 1407 to centralize this litigation in the Southern District of New York. This litigation currently consists of 34 actions pending in 13 districts, as listed on Schedule A. Since the filing of the motion, the Panel has been notified of 19 related federal actions.1
Defendant McKesson Corporation supports centralization in the Southern District of New York. Plaintiffs in 27 actions on the motion and three potential tag-along actions support centralization in the Eastern…
2Cases cited2 opinions
- In re Xarelto (Rivaroxaban) Products Liability LitigationUnited States Judicial Panel on Multidistrict Litigation · 2014
- In Re Glenn W. Turner Enterprises LitigationUnited States Judicial Panel on Multidistrict Litigation · 1973
3Cited by3 opinions
- In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability LitigationDistrict Court, W.D. Pennsylvania · 2026
- In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability LitigationDistrict Court, N.D. California · 2026
- Proven Networks, LLC v. F5 Networks, Inc.District Court, N.D. California · 2021